A new angiogenesis inhibitor targeting multiple tyrosine kinases offers new hope for treating tumors
Guest
A guest blog from co-Editor-in-Chief of Vascular Cell, Jan Kitajewski, in which he discusses the potential of using the newly developed lenvatinib as… Read more »